The Journal of Experimental Medicine
VeriKine-HS Human IFN-Beta
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published 17 December 2001. doi:10.1084/jem.194.12.1755
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 520K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kakimi, K.
Right arrow Articles by Guidotti, L. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kakimi, K.
Right arrow Articles by Guidotti, L. G.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© Rockefeller University Press, 0022-1007/2001/12/1755/ $5.00
The Journal of Experimental Medicine, Volume 194, Number 12, December 17, 2001 1755-1766

Original Article

Blocking Chemokine Responsive to {gamma}–2/Interferon (IFN)-{gamma} Inducible Protein and Monokine Induced by IFN-{gamma} Activity In Vivo Reduces the Pathogenetic but not the Antiviral Potential of Hepatitis B Virus–specific Cytotoxic T Lymphocytes

Kazuhiro Kakimi1, Thomas E. Lane3, Stefan Wieland1, Valerie C. Asensio2, Iain L. Campbell2, Francis V. Chisari1 and Luca G. Guidotti1

1 Departments of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037
2 Departments of Neuropharmacology, The Scripps Research Institute, La Jolla, CA 92037
3 Department of Molecular Biology and Biochemistry, University of California at Irvine, Irvine, CA 92697

Address correspondence to Luca G. Guidotti, The Scripps Research Institute, Dept. of Molecular and Experimental Medicine, 10550 North Torrey Pines Rd., La Jolla, CA 92037. Phone: 858-784-2758; Fax: 858-784-2960; E-mail: guidotti{at}scripps.edu

Using transgenic mice that replicate hepatitis B virus (HBV) at high levels in the liver as recipients of HBV-specific cytotoxic T lymphocytes (CTLs), we showed that the chemokines responsive to {gamma}–2/IFN-{gamma} inducible protein ([Crg2]IP-10) and monokine induced by interferon-{gamma} (Mig) are rapidly and strongly induced in the liver after CTL transfer. The transferred CTLs produce neither chemokine; rather, they activate (via the secretion of IFN-{gamma}) hepatocytes and nonparenchymal cells of the liver to produce (Crg2)IP-10 and Mig. Importantly, blocking these chemokines in vivo reduces the recruitment of host-derived lymphomononuclear cells into the liver and the severity of the liver disease without affecting the IFN-{gamma}–dependent antiviral potential of the CTLs. The finding that neutralization of these chemokines is associated with maintenance of antiviral effects but diminished tissue damage may be significant for the development of immunotherapeutic approaches for the treatment of chronic HBV infection.

Key Words: chemokines • hepatitis B virus • infectious immunity-virus • liver


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS